FI4122923T3 - Oksadiatsolijohdannainen - Google Patents

Oksadiatsolijohdannainen

Info

Publication number
FI4122923T3
FI4122923T3 FIEP21770862.7T FI21770862T FI4122923T3 FI 4122923 T3 FI4122923 T3 FI 4122923T3 FI 21770862 T FI21770862 T FI 21770862T FI 4122923 T3 FI4122923 T3 FI 4122923T3
Authority
FI
Finland
Prior art keywords
oxadiazol
substituted
independently selected
hydroxy
alkyl
Prior art date
Application number
FIEP21770862.7T
Other languages
English (en)
Finnish (fi)
Inventor
Yoshiaki Isobe
Tomoyuki Tanaka
Hirotaka Miyachi
Original Assignee
Sumitomo Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Pharma Co Ltd filed Critical Sumitomo Pharma Co Ltd
Application granted granted Critical
Publication of FI4122923T3 publication Critical patent/FI4122923T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FIEP21770862.7T 2020-03-17 2021-03-16 Oksadiatsolijohdannainen FI4122923T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020046138 2020-03-17
PCT/JP2021/010628 WO2021187486A1 (ja) 2020-03-17 2021-03-16 オキサジアゾール誘導体

Publications (1)

Publication Number Publication Date
FI4122923T3 true FI4122923T3 (fi) 2025-11-12

Family

ID=77768228

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP21770862.7T FI4122923T3 (fi) 2020-03-17 2021-03-16 Oksadiatsolijohdannainen

Country Status (16)

Country Link
US (2) US12624011B2 (cg-RX-API-DMAC7.html)
EP (1) EP4122923B1 (cg-RX-API-DMAC7.html)
JP (2) JP7637121B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220154208A (cg-RX-API-DMAC7.html)
CN (1) CN115515943B (cg-RX-API-DMAC7.html)
AU (1) AU2021239631B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022017530A2 (cg-RX-API-DMAC7.html)
CA (1) CA3170273A1 (cg-RX-API-DMAC7.html)
DK (1) DK4122923T3 (cg-RX-API-DMAC7.html)
ES (1) ES3041051T3 (cg-RX-API-DMAC7.html)
FI (1) FI4122923T3 (cg-RX-API-DMAC7.html)
MX (1) MX2022011483A (cg-RX-API-DMAC7.html)
PH (1) PH12022552373A1 (cg-RX-API-DMAC7.html)
PT (1) PT4122923T (cg-RX-API-DMAC7.html)
TW (1) TWI879917B (cg-RX-API-DMAC7.html)
WO (1) WO2021187486A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12624011B2 (en) * 2020-03-17 2026-05-12 Sumitomo Pharma Co., Ltd. Oxadiazole derivative
JP7653399B2 (ja) 2021-09-22 2025-03-28 住友ファーマ株式会社 オキサジアゾール誘導体を含有する医薬組成物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1227978A (cg-RX-API-DMAC7.html) * 1968-09-13 1971-04-15
TW200715993A (en) 2005-06-15 2007-05-01 Senomyx Inc Bis-aromatic amides and their uses as sweet flavor modifiers, tastants, and taste enhancers
RU2426731C2 (ru) * 2005-12-23 2011-08-20 Ф. Хоффманн-Ля Рош Аг Производные арил-изоксазоло-4-ил-оксадиазола
RU2009127095A (ru) * 2006-12-15 2011-01-20 Эбботт Лэборетриз (Us) Новые оксадиазольные соединения
GB0723814D0 (en) * 2007-12-05 2008-01-16 Glaxo Group Ltd Compounds
JP5746612B2 (ja) * 2008-03-19 2015-07-08 オーリムメッド・ファルマ・インコーポレーテッド 中枢神経系疾患および障害の治療に有効な新規化合物
WO2010017132A1 (en) * 2008-08-04 2010-02-11 Chdi, Inc. Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
US20110224304A1 (en) * 2008-11-14 2011-09-15 Dainippon Sumitomo Pharma Co., Ltd. Biphenylacetamide derivative
JP2012001537A (ja) * 2010-05-19 2012-01-05 Dainippon Sumitomo Pharma Co Ltd ビフェニルアセトアミド誘導体からなる医薬
WO2011145669A1 (ja) * 2010-05-19 2011-11-24 大日本住友製薬株式会社 アミド誘導体
US9199981B2 (en) 2011-09-01 2015-12-01 Novartis Ag Compounds and compositions as C-kit kinase inhibitors
SI2772482T1 (sl) * 2011-10-27 2016-06-30 Taisho Pharmaceutical Co., Ltd. Derivat azola
JP2013221025A (ja) * 2012-04-19 2013-10-28 Dainippon Sumitomo Pharma Co Ltd ビフェニルアセトアミド誘導体の製造方法及びその中間体
WO2014072957A1 (en) * 2012-11-12 2014-05-15 Lupin Limited Thiazole derivatives as alpha 7 nachr modulators
JP6387669B2 (ja) * 2013-04-26 2018-09-12 大正製薬株式会社 アゾール誘導体を含有する医薬
WO2015161014A1 (en) * 2014-04-17 2015-10-22 Merck Sharp & Dohme Corp. Heterocyclic cgrp receptor antagonists
TW201642855A (zh) 2015-03-10 2016-12-16 健臻公司 用於治療蛋白質病變之方法
WO2017066103A1 (en) * 2015-10-16 2017-04-20 Aurimmed Pharma, Inc. Novel compounds advantageous in the treatment of central nervous system diseases and disorders
TW201729807A (zh) * 2015-10-30 2017-09-01 Ptc治療公司 用於治療癲癇的方法
US12624011B2 (en) * 2020-03-17 2026-05-12 Sumitomo Pharma Co., Ltd. Oxadiazole derivative

Also Published As

Publication number Publication date
US12624011B2 (en) 2026-05-12
US20230092498A1 (en) 2023-03-23
US20230265061A1 (en) 2023-08-24
TWI879917B (zh) 2025-04-11
ES3041051T3 (en) 2025-11-06
EP4122923A4 (en) 2024-04-24
KR20220154208A (ko) 2022-11-21
DK4122923T3 (da) 2025-12-15
CA3170273A1 (en) 2021-09-23
AU2021239631A8 (en) 2022-12-01
TW202146392A (zh) 2021-12-16
JP2025081449A (ja) 2025-05-27
WO2021187486A1 (ja) 2021-09-23
CN115515943B (zh) 2024-07-09
PH12022552373A1 (en) 2023-12-18
AU2021239631B2 (en) 2026-05-14
PT4122923T (pt) 2025-12-03
JP7637121B2 (ja) 2025-02-27
BR112022017530A2 (pt) 2022-10-18
EP4122923B1 (en) 2025-09-10
CN115515943A (zh) 2022-12-23
EP4122923A1 (en) 2023-01-25
JPWO2021187486A1 (cg-RX-API-DMAC7.html) 2021-09-23
AU2021239631A1 (en) 2022-11-10
US11718592B2 (en) 2023-08-08
MX2022011483A (es) 2022-10-07

Similar Documents

Publication Publication Date Title
JP2019077725A5 (cg-RX-API-DMAC7.html)
RU2017121044A (ru) Производные амидотиадиазола в качестве ингибиторов надфн-оксидазы
RU2011153772A (ru) Фторированные аминотриазольные производные
RU2010106854A (ru) Производные 2-аза-бицикло[3.3.0]октана
AU2009266756B2 (en) Triazole derivative or salt thereof
US20100234349A1 (en) Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer
CA2497351A1 (fr) Nouveaux derives d'aminoindazoles a titre de medicaments et compositions pharmaceutiques les renfermant
RU2481330C2 (ru) Азотсодержащее ароматическое гетероциклическое соединение
RU2005121897A (ru) Производные аминоиндазолов и их применение в качестве ингибиторов киназ
JP2010534647A5 (cg-RX-API-DMAC7.html)
EA020008B1 (ru) Производные оксазина и их применение для лечения неврологических нарушений
JP2008523041A5 (cg-RX-API-DMAC7.html)
RU2008116828A (ru) Комбинированный метод терапии замещенными оксазолидинонами для профилактики и лечения нарушений церебрального местного кровообращения
KR100909953B1 (ko) 항진균 활성을 갖는 트라이아졸 유도체, 이의 제조방법 및이를 함유하는 약학 조성물
RU2011116232A (ru) Пиразолопиридиновые производные как ингибиторы надфн-оксидазы
RU2017120217A (ru) 2-амино-5,5-дифтор-6-(фторметил)-6-фенил-3,4,5,6-тетрагидпропиридины в качестве ингибиторов bace1
JP2022546029A5 (cg-RX-API-DMAC7.html)
RU2008107733A (ru) Ингибиторы gsk-3
JP2014523400A5 (cg-RX-API-DMAC7.html)
RU2013130878A (ru) Гидроксилированные производные аминотриазола в качестве агонистов рецептора alx
RU2013125338A (ru) Производные триазола в качестве лигандов рецепторов гамк
US20170066753A1 (en) Oxadiazine compounds and methods of use thereof
JP2024516826A5 (cg-RX-API-DMAC7.html)
JP2004508366A5 (cg-RX-API-DMAC7.html)
JP2022505143A5 (cg-RX-API-DMAC7.html)